Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 13/20 | 0.57 |
| ▸ | EGFR | P00533 | 5/20 | 0.56 |
| ▸ | GAK | O14976 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | FLT1 | P17948 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13963533 | 0.95 | FGFR1 (0.59) | KDM1AEGFRGAKKDRFGFR1 | |
| SCHEMBL20127270 | 0.82 | FBP1 (0.43) | KDM1AEGFRGAKKDRFGFR1 | |
| SCHEMBL13523340 | 0.82 | KDM1A (0.58) | KDM1AEGFRGAKKDR | |
| SCHEMBL1010409 | 0.82 | ENPP1 (0.57) | EGFRGAKKDRFGFR1FLT1 | |
| SCHEMBL1012227 | 0.82 | ENPP1 (0.57) | EGFRGAKKDRFGFR1FLT1 | |
| SCHEMBL1011566 | 0.82 | ENPP1 (0.57) | EGFRGAKKDRFGFR1FLT1 | |
| SCHEMBL1012438 | 0.82 | ENPP1 (0.57) | EGFRGAKKDRFGFR1FLT1 | |
| SCHEMBL8812445 | 0.81 | ENPP1 (0.58) | EGFR | |
| SCHEMBL2476964 | 0.81 | RET (0.55) | EGFRGAKKDRFGFR1FLT1 | |
| Hydrochloric Acid SCHEMBL28084915 | 0.81 | ENPP1 (0.56) | EGFRGAKKDRFGFR1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210114993-A1 | COMPOUNDS FOR TREATING ILK-MEDIATED DISEASES | THE CLEVELAND CLINIC FOUNDATION | 2021-04-22 | — | — | US | disclosed |
| EP-3100730-A1 | N-(3-ETHYNYLPHENYL)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE FOR USE IN THE TREATMENT OF NSCLC | OSI Pharmaceuticals, LLC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| EP-1853300-B1 | METHODS OF USING DEATH RECEPTOR AGONISTS AND EGFR INHIBITORS | GENENTECH INC (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2162444-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ERLOTINIB HYDROCHLORIDE | HETERO DRUGS LTD (IN) | 2014-06-04 | — | — | EP | disclosed |
| US-20130084281-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | TRAGARA PHARMACEUTICALS, INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130084281-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | TRAGARA PHARMACEUTICALS, INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-8389531-B2 | Process for erlotinib hydrochloride | HETERO DRUGS LIMITED (IN) | 2013-03-05 | — | — | US | disclosed |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | SLIWKOWSKI MARK X (US) | 2012-10-04 | — | — | US | disclosed |
| EP-2162444-A2 | AN IMPROVED PROCESS FOR ERLOTINIB HYDROCHLORIDE | Hetero Drugs Limited (IN) | 2010-03-17 | — | — | EP | disclosed |
| WO-2009070546-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009007984-A2 | AN IMPROVED PROCESS FOR ERLOTINIB HYDROCHLORIDE | HETERO DRUGS LIMITED (IN) | 2009-01-15 | — | — | WO | disclosed |
| US-20090017024-A1 | Methods and Compositions for the Treatment of Cancer, Tumors, and Tumor-Related Disorders | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090017024-A1 | Methods and Compositions for the Treatment of Cancer, Tumors, and Tumor-Related Disorders | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| EP-1233948-B1 | STABLE POLYMORPH OF N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | OSI PHARM INC (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007013950-A9 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH INC (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007013950-A2 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070020261-A1 | Combination therapy of her expressing tumors | GENENTECH, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070020261-A1 | Combination therapy of her expressing tumors | GENENTECH, INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210114993-A1 | COMPOUNDS FOR TREATING ILK-MEDIATED DISEASES | ILK, ITGB1, ITGA2B | KDM1A 575/4885EGFR 593/4885GAK 791/4885 |
| US-20130084281-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | TP53, VHL, TSG101 | KDM1A 3329/4885EGFR 533/4885GAK 1682/4885 |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | KDM1A 3797/4885EGFR 2/4885GAK 1055/4885 |
| US-20090017024-A1 | Methods and Compositions for the Treatment of Cancer, Tumors, and Tumor-Related Disorders | TP53, VHL, TSG101 | KDM1A 3329/4885EGFR 533/4885GAK 1682/4885 |
| US-20070020261-A1 | Combination therapy of her expressing tumors | ERBB2, EGFR, ERBB3 | KDM1A 3797/4885EGFR 2/4885GAK 1055/4885 |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | KDM1A 3797/4885EGFR 2/4885GAK 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.